TWiV 811: COVID-19 clinical update #82 with Dr. Daniel Griffin
In COVID-19 clinical update #82, Daniel Griffin reviews vaccines for 5-12 years old, safety of a third vaccine dose, Oklahoma reinfection data, Regencov outcomes, Pfizer protease inhibitor, impact of Tocilizumab, and incidence of long COVID.
Hosts:\xa0Daniel Griffin and Vincent Racaniello
Subscribe (free):\xa0iTunes,\xa0Google Podcasts,\xa0RSS,\xa0email
Become a\xa0patron\xa0of\xa0TWiV!
Links for this episode- Data on Pfizer-BioNTech in 5-12 year olds (Pfizer)
- Safety of additional vaccine dose (MMWR)
- Oklahoma reinfection rates (OK DOH)
- Regencov outcomes (NEJM)
- Pfizer protease inhibitor trial (Pfizer)
- WHO recommends antibody therapy (Hosp Health)
- Tocilizumab use in hospitalized patients (Resp Care)
- Long COVID (PLoS Medicine)
- Letters read\xa0on TWiV 811
- Timestamps by Jolene. Thanks!
Intro music is by\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv